2024-11-09 - Analysis Report
##  Merck & Co Inc (MRK) Stock Analysis

**1. Performance Comparison:**

Merck & Co Inc (MRK) is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal health products.

- **Cumulative Return:** MRK: 56.92%, VOO (S&P 500): 141.71%
- **Return Difference:** -84.79% (Relative Outperformance: 1.84)

MRK has significantly underperformed the S&P 500 over the analyzed period.  The relative outperformance score of 1.84 indicates that MRK's performance has been worse than 84% of the historical data points. 

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|-----|-------|-----|
| 2015-2017 | -1.6% | 18.1% | -31.8% | 0.9 |
| 2016-2018 | 45.6% | 17.0% | 20.9% | 0.7 |
| 2017-2019 | 51.2% | 17.0% | 8.1% | 0.7 |
| 2018-2020 | 45.5% | 27.2% | 6.4% | 0.7 |
| 2019-2021 | 6.3% | 27.2% | -83.6% | 0.6 |
| 2020-2022 | 26.3% | 27.2% | 8.6% | 0.5 |
| 2021-2023 | 41.1% | 19.8% | 12.3% | 0.3 |
| 2022-2024 | 31.6% | 23.2% | 7.0% | 0.3 |

MRK's beta has consistently been below 1, suggesting lower volatility compared to the broader market. However, the alpha (excess return) has been erratic, with negative returns in certain periods indicating underperformance relative to the market.

**2. Recent Price Action:**

- **Closing Price:** 101.17 (Last Market: 102.97)
- **5-day Moving Average:** 101.46
- **20-day Moving Average:** 105.57
- **60-day Moving Average:** 111.79

The current price is below all three moving averages, suggesting potential for a downward trend.  

**3. Technical Indicators:**

- **RSI:** 17.85: This suggests the stock is in oversold territory, potentially hinting at a bounce back.
- **PPO:** -0.23: A negative PPO indicates a downtrend, aligning with the price action and moving averages.
- **Delta_Previous_Relative_Divergence:** -18.58: Negative divergence suggests a short-term bearish trend.
- **Expected Return:** 0.0%: This suggests the stock is expected to perform in line with the S&P 500 over the long term.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2024-11-06 | 1.87 | 15.96 B$ |

Recent earnings have been slightly below analyst expectations, with the most recent earnings report showing an EPS of 1.25 vs. an expected EPS of 1.30.  Despite the recent performance, analysts remain generally positive about MRK's long-term prospects, citing strong growth in its oncology and vaccine segments.

**5. Financial Data:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $16.66B | 75.51% |
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |
| 2023-09-30 | $15.96B | 73.29% |

MRK continues to demonstrate strong profitability, with a consistently high profit margin, indicating efficiency in managing its operations.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $44.50B | 7.09% |
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |
| 2023-09-30 | $41.25B | 11.50% |

Equity growth has been consistent, reflecting the company's strong financial position. ROE is a key metric for evaluating profitability, and MRK has shown significant profitability except in Q4 2023, likely due to one-time factors.

**6. News and Recent Issues:**

* **Recent Earnings News:** MRK reported its Q3 2024 earnings on November 6, 2024, with an EPS of 1.25, slightly below analyst estimates. 
* **Market Outlook:**  Analysts remain bullish on MRK's long-term growth potential, citing its strong product pipeline and market share in key segments like oncology and vaccines.  
* **Analyst Opinions and Performance Highlights:** According to FINBOLD, analysts remain optimistic about MRK, with an average rating of "Buy".  Analysts highlight MRK's strong dividend yield and stable business model. 

**7. Summary:**

MRK is a large pharmaceutical company with a solid financial position and strong revenue and profitability. However, it has underperformed the S&P 500 significantly in recent years, with the latest earnings release coming in slightly below estimates. The stock is currently in oversold territory, suggesting potential for a bounce back.  However, technical indicators point towards a potential short-term downtrend.  Analysts remain optimistic about MRK's long-term growth prospects, citing its strong product pipeline and market share in key segments.  

**8. Recommendation:**

Based on the analysis, while MRK appears undervalued and may be an attractive long-term investment due to its strong fundamentals and potential for growth, investors should be cautious given the recent underperformance and potential for short-term volatility.  

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. It is essential to conduct your own research and consult with a qualified financial professional before making any investment decisions. 
